Sagimet Biosciences (SGMT) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Sagimet Biosciences insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $4.9M of SGMT stock on the open market.
Get emailed when insiders cluster-buy stocks like SGMT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SGMT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $4.5M | 5 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $105K | 4 |
| Q4 2025 | — | 0 | $290K | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Sagimet Biosciences Inc. insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $4.9M. 4 of 10 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 17SEC | George KembleDirector | Sell Plan | 350,98762,161 held (−85%) | $10.23 | $3.6M | -12.7% | — |
| Aug 12SEC | George KembleDirector | Sell Plan | 20,20662,161 held (−25%) | $9.95 | $201K | -10.3% | — |
| Jul 22SEC | David HappelCEO, President | Sell | 64,051741,570 held (−8%) | $7.76 | $497K | +15.1% | — |
| Jul 22SEC | George KembleDirector | Sell Plan | 18,84462,161 held (−23%) | $7.46 | $141K | +19.7% | — |
| Jul 22SEC | Elizabeth RozekGeneral Counsel | Sell | 10,545224,414 held (−4%) | $7.76 | $82K | +15.1% | — |
| Feb 12SEC | David HappelCEO, President | Sell | 12,101677,621 held (−2%) | $5.36 | $65K | +66.6% | — |
| Feb 12SEC | Eduardo Bruno MartinsChief Medical Officer | Sell | 3,640103,296 held (−3%) | $5.36 | $20K | +66.6% | — |
| Feb 12SEC | Elizabeth RozekGeneral Counsel | Sell | 2,622190,959 held (−1%) | $5.36 | $14K | +66.6% | — |
| Feb 12SEC | Thierry ChaucheCFO | Sell | 1,31215,688 held (−8%) | $5.36 | $7K | +66.6% | — |
| Nov 21SEC | George KembleChair | Sell Plan | 37,68881,005 held (−32%) | $7.69 | $290K | +16.1% | — |
Insiders at Sagimet Biosciences Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| George KembleDirector | — | $4.2M | Aug 17, 2026 | — |
| David HappelCEO, President | — | $562K | Jul 22, 2026 | — |
| Elizabeth RozekGeneral Counsel | — | $96K | Jul 22, 2026 | — |
| Eduardo Bruno MartinsChief Medical Officer | — | $20K | Feb 12, 2026 | — |
| Thierry ChaucheCFO | — | $7K | Feb 12, 2026 | — |
SGMT stock: common questions
Are Sagimet Biosciences Inc. insiders buying SGMT stock?
In the past 12 months, 0 insiders reported open-market purchases of SGMT worth $0.
Are Sagimet Biosciences Inc. insiders selling SGMT stock?
5 insiders reported sales worth $4.9M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SGMT's 52-week range?
Over the past year SGMT has traded between $4.55 and $11.17. It last closed at $8.93 on Oct 9, 2026.